Chlorion Pharma

Chlorion Pharma is a Canadian biotechnology company focused on developing first-in-class therapies for central nervous system (CNS) disorders by restoring neuronal chloride homeostasis. The company's primary strategy involves the development of small molecule enhancers of the Potassium-chloride cotransporter 2 (KCC2), a protein essential for inhibitory neurotransmission in the brain and spinal cord. By targeting KCC2, Chlorion aims to treat conditions where inhibitory signaling is impaired, such as chronic neuropathic pain, epilepsy, and spinal cord injuries. The company's research is rooted in the work of scientific founders from the CERVO Brain Research Centre and Université Laval. Chlorion is currently advancing its lead candidates through pre-clinical development to address significant unmet needs in neurology.